EZH2 and diffuse large B-cell lymphoma: Furthermore, the identification of this mutational mechanism of resistance confirms that EZH2 can function as an oncogenic driver in GCB-DLBCL, thus further validating the therapeutic potential of EZH2-targeted agents.